期刊
CANCER
卷 116, 期 20, 页码 4718-4726出版社
WILEY
DOI: 10.1002/cncr.25259
关键词
epithelial membrane protein-2; endometrial cancer; metachronous; tissue microarray; tumor biomarker
类别
资金
- National Institutes of Health [T32 CA 009056-32, HD48540, CA131756]
- Early Detection Research Network NCI [CA-86, 366]
- Iris Cantor Seed Grant
- UCLA Jonsson Comprehensive Cancer Center
BACKGROUND: Endometrial cancer (EC) is a common malignancy worldwide. It is often preceded by endometrial hyperplasia, whose management and risk of neoplastic progression vary. Previously, the authors have shown that the tetraspan protein epithelial membrane protein-2 (EMP2) is a prognostic indicator for EC aggressiveness and survival. Here the authors validate the expression of EMP2 in EC, and further examine whether EMP2 expression within pre-neoplastic lesions is an early prognostic biomarker for EC development. METHODS: A tissue microarray (TMA) was constructed with a wide representation of benign and malignant endometrial samples. The TMA contains a metachronous cohort of cases from individuals who either developed or did not develop EC. Intensity and frequency of EMP2 expression were assessed using immunohistochemistry. RESULTS: There was a stepwise, statistically significant increase in the average EMP2 expression from benign to hyperplasia to atypia to EC. Furthermore, detailed analysis of EMP2 expression in potentially premalignant cases demonstrated that EMP2 positivity was a strong predictor for EC development. CONCLUSIONS: EMP2 is an early predictor of EC development in preneoplastic lesions. In addition, combined with our previous findings, these results validate EMP2 as a novel biomarker for EC development. Cancer 2010; 116: 4718-26. (C) 2010 American Cancer Society.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据